Checkpoint Therapeutics (CKPT) Downgraded to Hold at Zacks Investment Research
Checkpoint Therapeutics (NASDAQ:CKPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
Separately, HC Wainwright initiated coverage on shares of Checkpoint Therapeutics in a report on Friday, December 8th. They issued a “buy” rating and a $11.00 price objective for the company.
TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/22/checkpoint-therapeutics-ckpt-downgraded-to-hold-at-zacks-investment-research.html.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.